Table 3. Pharmacotherapeutic Options for Symptomatic Treatment of P Drug
Dosage Form MAO-B inhibitors
rasagiline Azilect
0.5, 1 mg tablets
Monotherapy: 1 mg/d Adjunctive: 0.5 mg/d; if insufficient clinical response, may be increased to 1 mg/d
> Monot > Contra propox
> Avoid d > Use low > Not as screeni
selegiline (l-deprenyl) Eldepryl, generics
orally disintegrating selegiline Zelapar
5 mg capsule
10 mg/d divided 5 mg at breakfast and lunch; max 10 mg/d
1.25 mg orally
disintegrating tablet (not swallowed)
1.25 mg q am (before breakfast and without liquid) for 6 wk; thereafter may be increased to 2.5 mg q am; max 2.5 mg/d
> Adjunc carbido
> Adjunc > Contra meperi
> Contra > Avoid a
Recommended Dosage Commen
> Avoid S > Not as screeni
> Deliver Dopamine agonists
apomorphine Apokyn
10 mg/mL in 3 mL cartridge
Initial: 0.2 mL SQ injection; titrate up (based on effectiveness/tolerance) to max 6 doses/d prn
> Adjunc may ca
> Contra > Cautio
> Somno > Pretrea clinical
bromocriptine Parlodel
pergolide* Permax
pramipexole Mirapex
2.5 mg tablet 5 mg capsule
0.05, 0.25, 1 mg tablets
0.125, 0.25, 0.5, 1.0, 1.5 mg tablets
12
of 2.5 mg tablet bid with meals; titrate up q 14–28 d by 2.5 mg/d to max 100 mg/d
0.05 mg/d first 2 d; titrate up 0.1–0.15 mg/d (divided doses tid) q 3 d for 12 d, then by 0.25 mg/d q 3 d to max 5 mg/d
0.125 mg tid for 1 wk; titrate up each wk for 6 wk with 0.25, 0.5, 0.75, 1.0, 1.25, 1.5 mg tid
ropinirole Requip
Requip XL
0.25, 0.5, 1, 2, 3, 4, 5 mg tablets
2, 4, 6, 8, 12 mg
0.25 mg tid for 1 wk; then titrate up each wk to 9 mg/d by week 8, then by 3 mg/d to 24 mg/d
2 mg qd for 1-2 wk; increases of 2 mg/d at 1 wk or longer intervals to 24 mg/d
> Somno > Rarely
renal im
> Adjunc > Contra ergot a
> Adjunc > Somno > Monito
> Monot > Titrate sleep o
> Not as screeni
> Discon
> Monot > Somno > Not as screeni
> Discon
